Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV01-A02
- Development stage
- Phase 2
- Lead developer
- Neuroventi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NV01-A02 is a chewable small molecule pill developed by Neuroventi for the treatment of autism spectrum disorder and Fragile X syndrome. It acts as a **precise modulator of specific neurotransmitter receptors** related to improving social function and reducing stereotyped behaviors. The drug is being evaluated primarily in pediatric populations and aims to address core symptoms of sociality and behavioral rigidity in autism, a domain historically resistant to effective drug therapies. NV01-A02 has orphan drug designation for Fragile X syndrome[1][2][3][4]. Clinical trials have established its safety profile, with ongoing phase II studies for autism spectrum disorder in children. Neuroventi holds global patents for NV01-A02 in several major regions, including South Korea, the US, EU, China, and Japan[1].
- Brand names
- NV01-A02NV-01-A02NV 01-A02
- Other names
- NV01-A02NV-01-A02NV 01-A02NV01 A02NV-01 A02NV 01 A02
02
Targets
DRD (Dopamine receptors)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on NV01-A02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV01-A02.